Hello everyone, and welcome to the middle of the week. Although this is often a slow time of year, it’s been a busy few days, lately, right? Well, that can only mean one thing – time for another cup of stimulation. Neurons you need a little help, you know? So feel free to join us. Meanwhile, we have, once again, some data gathered to help you in your own journey. I hope this is a productive day and not have us in mind when something fascinating …
The Food and Drug Administration US approved the first biosimilar version of Enbrel, sold by Amgen and used to treat psoriasis and rheumatoid arthritis , among other things. However, the commercial availability may be delayed until March because the US courts have ruled companies must wait 180 days after winning approval from the FDA before sales can begin. The biosimilar version will be called Erelzi and marketed by Sandoz, the generic unit of Novartis.
A British charity called the National AIDS Trust is becoming crowdfunding to finance a legal challenge against the National Health Service Pharmaphorum he says. The NHS refused to cover HIV prevention pill called Truvada, sold by Gilead Sciences, because the agency believes that local authorities have the responsibility to pay for these treatments. NAT supports the NHS must do so due to HIV infection is increasing among gay men in England.
An increasing number of elderly patients across the country are multiple medications for the treatment of chronic diseases, increasing their chances of interaction with other drugs and dangerous severe side effects Kaiser health News informs us. In fact, older adults account for approximately 35 percent of all hospital stays, but more than half of the visits are marked by drug-related complications.
Express Scripts will start a program in March that is designed to limit costs incurred by patients with diabetes for treatment , according to The St. Louis Business Journal . The administrator pharmacy benefit believes the spending limit per patient reduce rising costs of half of the members in participating health plans and also increase compliance rates of medication for patients who participated in a 5 percent .
Teva Pharmaceuticals is a closure of a plant in Pomona, N. Y., R & D and the elimination of 236 jobs, according to a notice filed with state authorities. A spokeswoman says only 80 employees will be affected and some jobs may be moved elsewhere.
GlaxoSmithKline expects to exceed sales forecasts for a group of vaccines that were acquired last year from Novartis as part of an asset swap Bloomberg News tells us.
A drug called Niclocide, which is already on the market to treat worm infections, and another being tested against diseases of the liver can also help treat infection Zika virus NBC News informs us.
Cancer Research UK initiated a clinical trial of the first of its kind to explore whether the cells of pancreatic cancer can earn more sensitive to chemotherapy and radiotherapy PharmaTimes He says.
Impax Laboratories issued a voluntary recall for a portion of their lamotrigine orally disintegrating tablets due to incorrect labeling of their blisters Inpharma technologist writes.
pharmaceutical Rigel said its experimental drug, fostamatinib, met the primary endpoint in a Phase 3 study of patients with an autoimmune disease of platelet TheStreet reports .
Vectura Group said his therapy Flutiform did not meet the primary endpoint in a trial of the final stage for the treatment of chronic obstructive pulmonary disease Reuters says.